• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1245876 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type8 I4 K0 Y. e# ^- I4 K/ r
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
! H; e6 S- E1 O+ Author Affiliations
6 d, a$ r# ^. i# a% ]$ O7 a2 E8 t, Q8 d
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 5 V6 B! B) |( T* p6 D$ L
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 5 X3 V1 G! d2 i
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 7 m2 Y1 Y# O$ h$ P5 o2 ^3 ?0 M
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan , \1 ?# Y4 u. ]% k8 N8 h
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 4 w) y4 b. ?& ^) k
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
( W5 m) O( A6 \. P, q# m' w: h' j7Kinki University School of Medicine, Osaka 589-8511, Japan
; K7 ^+ K, a7 T: p1 f8Izumi Municipal Hospital, Osaka 594-0071, Japan . N6 K1 h5 f0 W% }
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
' k4 p7 a6 T& G) s/ E3 A' j  Z6 dCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
6 m: B, n* J# `$ z$ `( {AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. , u5 h1 S4 C1 M! [7 G
, V8 H' F0 S5 M) s
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type & q. D' p) _' N, ~' G# B5 q7 G
$ k6 N+ s& V# q2 o" N% Y
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato $ \& y/ j% O& G! i% K$ q; X' C4 d
/ n% c' q) o6 _+ M- w5 m
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
( `+ f) t$ d! s' Q8 b9 H& T2 K
7 I' Y: l8 ]: uPublished online on: Thursday, December 1, 2011
4 m% p7 |& D9 ^+ ~# }( u$ V' W8 b) P% _1 \. I
Doi: 10.3892/ol.2011.507
! X+ `5 R2 `6 l7 Z0 n: A! t$ R! V& b/ J" w
Pages: 405-410 7 \; X9 N  f4 C9 |0 W/ @

' T2 f$ e9 D+ l& MAbstract:- z$ g) _" ?, ^) c# \& s$ ]
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
% ]5 g% U7 d( D" L% q
: w# n9 `1 v/ v1 l/ T/ i, g
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population8 S; [7 J$ Z- f( m7 `% G9 u
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 5 W. k; O: u# N  B7 k. y
+ Author Affiliations/ U: S0 I7 k6 K( K
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu 6 f3 e- ~/ R/ n0 |' S7 S% l1 i
2Department of Thoracic Surgery, Kyoto University, Kyoto
0 m1 W7 n, D8 `0 X3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan   E% l7 G5 t! j9 g
&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
+ w# H1 D* L( F% ^% g' F+ r- jReceived September 3, 2010.   N4 k% ]: m9 c, ~
Revision received November 11, 2010. : l6 U/ V1 T8 P) I! J( b. ]
Accepted November 17, 2010.
$ Y# j& j% P' h9 `. mAbstract( G0 m' V/ u. w9 X# c( Q. q
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
, r4 U% l; n& _8 l. ~Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
$ f8 t' o6 \) h' x& BResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
) i9 ~  j2 t8 |8 E" T. _9 b; rConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. $ y$ \2 [  ]" l1 \4 m8 X
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
+ ^: n. r- ?. ^7 @今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
) r0 ~2 Y/ w) X" v, U
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy+ m# [; C3 v4 e  y0 R
http://clinicaltrials.gov/ct2/show/NCT01523587/ A& c' h9 L5 o) v+ x. `2 G$ S- M
7 W$ N2 q8 w& |. Y! h$ w4 [
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
7 s  c9 H& d; F2 ]: h, ]% T( rhttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑
0 Q8 l: c6 c3 u) H. |$ T! w# O7 }8 }# T# ~4 _9 N+ p
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
% j  X7 m5 a. U: h5 q3 ]至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦

( _8 a0 P8 }6 d  S. X/ |没有副作用是第一追求,效果显著是第二追求。
. i1 K2 ~; q& ~8 g/ J: |不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表